BOTHELL, Wash., Oct. 23 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics announced today that Alton Boynton, Ph.D., Company President, will present an update on the Company’s progress over the last six months, including ongoing long-term survival data from the Company’s clinical trials for Glioblastome multiforme. The presentation will take place Monday, October 30th at 8:30 AM Eastern Time at the CE Unterberg, Towbin Life Sciences Conference. The conference is being held at the Palace Hotel in New York City.
The presentation will be webcast live and available for replay for 90 days from the Northwest Biotherapeutics website, www.nwbio.com under the “Investor and Media” section.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company’s three lead product candidates are: DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Northwest Biotherapeutics
CONTACT: Lorie Calvo of Northwest Biotherapeutics, +1-425-608-3008
Web site: http://www.nwbio.com/
